FR3120787B1 - Composition pharmaceutique topique comprenant de l’amitriptyline et une phase aqueuse alcaline - Google Patents

Composition pharmaceutique topique comprenant de l’amitriptyline et une phase aqueuse alcaline Download PDF

Info

Publication number
FR3120787B1
FR3120787B1 FR2102760A FR2102760A FR3120787B1 FR 3120787 B1 FR3120787 B1 FR 3120787B1 FR 2102760 A FR2102760 A FR 2102760A FR 2102760 A FR2102760 A FR 2102760A FR 3120787 B1 FR3120787 B1 FR 3120787B1
Authority
FR
France
Prior art keywords
amitriptyline
pharmaceutical composition
aqueous phase
alkaline aqueous
topical pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2102760A
Other languages
English (en)
Other versions
FR3120787A1 (fr
Inventor
Philippe Picaut
Frédéric Lallemand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Algotherapeutix SAS
Original Assignee
Algotherapeutix SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Algotherapeutix SAS filed Critical Algotherapeutix SAS
Priority to FR2102760A priority Critical patent/FR3120787B1/fr
Priority to JP2023557355A priority patent/JP2024510314A/ja
Priority to EP22713714.8A priority patent/EP4308093A1/fr
Priority to CN202280022714.5A priority patent/CN117500488A/zh
Priority to PCT/FR2022/050461 priority patent/WO2022195214A1/fr
Priority to US18/550,908 priority patent/US20240041766A1/en
Publication of FR3120787A1 publication Critical patent/FR3120787A1/fr
Application granted granted Critical
Publication of FR3120787B1 publication Critical patent/FR3120787B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une composition pharmaceutique topique sous forme d’émulsion huile dans eau comprenant une phase huileuse à base d’amitriptyline sous forme base et une phase aqueuse alcaline. L’invention porte également sur la composition selon l’invention pour son utilisation par voie topique dans le traitement des douleurs neuropathiques et de l’érythromélalgie.
FR2102760A 2021-03-19 2021-03-19 Composition pharmaceutique topique comprenant de l’amitriptyline et une phase aqueuse alcaline Active FR3120787B1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR2102760A FR3120787B1 (fr) 2021-03-19 2021-03-19 Composition pharmaceutique topique comprenant de l’amitriptyline et une phase aqueuse alcaline
JP2023557355A JP2024510314A (ja) 2021-03-19 2022-03-15 アミトリプチリン及びアルカリ性水相を含む局所用医薬組成物
EP22713714.8A EP4308093A1 (fr) 2021-03-19 2022-03-15 Composition pharmaceutique topique comprenant de l'amitriptyline et une phase aqueuse alcaline
CN202280022714.5A CN117500488A (zh) 2021-03-19 2022-03-15 包含阿米替林和碱性水相的局部药物组合物
PCT/FR2022/050461 WO2022195214A1 (fr) 2021-03-19 2022-03-15 Composition pharmaceutique topique comprenant de l'amitriptyline et une phase aqueuse alcaline
US18/550,908 US20240041766A1 (en) 2021-03-19 2022-03-15 Topical pharmaceutical composition comprising amitriptyline and an alkaline aqueous phase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2102760A FR3120787B1 (fr) 2021-03-19 2021-03-19 Composition pharmaceutique topique comprenant de l’amitriptyline et une phase aqueuse alcaline
FR2102760 2021-03-19

Publications (2)

Publication Number Publication Date
FR3120787A1 FR3120787A1 (fr) 2022-09-23
FR3120787B1 true FR3120787B1 (fr) 2024-04-26

Family

ID=75954034

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2102760A Active FR3120787B1 (fr) 2021-03-19 2021-03-19 Composition pharmaceutique topique comprenant de l’amitriptyline et une phase aqueuse alcaline

Country Status (6)

Country Link
US (1) US20240041766A1 (fr)
EP (1) EP4308093A1 (fr)
JP (1) JP2024510314A (fr)
CN (1) CN117500488A (fr)
FR (1) FR3120787B1 (fr)
WO (1) WO2022195214A1 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE32979B1 (en) 1968-03-07 1974-02-06 Unilever Ltd Spreadable fats
US4131576A (en) 1977-12-15 1978-12-26 National Starch And Chemical Corporation Process for the preparation of graft copolymers of a water soluble monomer and polysaccharide employing a two-phase reaction system
FR3065371B1 (fr) 2017-04-25 2021-05-21 Laboratoires Mayoly Spindler Composition pharmaceutique topique comprenant au moins de l'amitriptyline pour le traitement de douleurs neuropathiques peripheriques

Also Published As

Publication number Publication date
WO2022195214A1 (fr) 2022-09-22
FR3120787A1 (fr) 2022-09-23
EP4308093A1 (fr) 2024-01-24
JP2024510314A (ja) 2024-03-06
CN117500488A (zh) 2024-02-02
US20240041766A1 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
FR2826292B1 (fr) Emulsions huile dans huile comprenant une silicone, dispersions de telles emulsions et utilisation
BR0107042A (pt) Dispersões para a formulação de agentes fracamente ou ligeiramente solúveis
TNSN99053A1 (fr) Hydroxamides d'acides (4-arylsulfonylamino)-tetrahydro- pyranne-4-carboxyliques), procede pour leur preparation et compositions les contenant
EA200400765A1 (ru) Фармацевтические составы, содержащие соединения активного витамина d
TNSN98017A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant.
BE1002249A4 (fr) Compositions pharmaceutiques.
TNSN99055A1 (fr) Derives bicycliques d'acide hydroxamique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN05262A1 (fr) Acides carboxyliques alpha-substitues servant de modulateurs de ppar
FR3065371B1 (fr) Composition pharmaceutique topique comprenant au moins de l'amitriptyline pour le traitement de douleurs neuropathiques peripheriques
TNSN03130A1 (fr) Inhibiteurs de protease du vih, compositions les contenant, leurs utilisations pharmaceutiques et matieres pour leur synthese
TNSN96104A1 (fr) Trihydrate de metahensulfonate de (1s,2s)-1-(4-hydroxyphenyl) -2-(4-hydroxy-4-phenylpiperidine-1-yl)-1-propanol et composition pharmaceutique le contenant
HUP0000564A2 (hu) Olajos szuszpenzió alakú gyógyászati készítmények
EA200301019A1 (ru) Доставляемая перорально фармацевтическая композиция, включающая препарат с низкой растворимостью в воде (ингибитор cox-2), растворитель, жирную кислоту и органический амин
MA34553B1 (fr) Combinaisons contenant du n-(2-arylamino)arylsulfonamide substitué
FR3120787B1 (fr) Composition pharmaceutique topique comprenant de l’amitriptyline et une phase aqueuse alcaline
BE900564A (fr) Composition pharmaceutique pour le traitement d'arteriopathies peripheriques.
BRPI0520503A2 (pt) composições antiinflamatórias e métodos de uso
MA29145B1 (fr) Préparations pharmaceutiques pour le traitement de la cellulite
DK1267831T3 (da) Hidtil ukendt selvemulgerende system til lægemiddelindgift
FR3061002B1 (fr) Composition comprenant de l’acide hydroxyethylpiperazine ethane sulfonique et au moins un alkylpolyglucoside
TNSN01052A1 (fr) Metabolites du (-) - cis - 6 - phenyl - 5 - [4 -( 2-pyrrolidine -1- yl - ethoxy) - phenyl] - 5,6,7,8- tetrahydro - naphtalene - 2 - ol et compositions les contenant
EP1297824A3 (fr) Emulsion ultrafine contenant un dérivé haloalkynylique
TNSN01076A1 (fr) Associations de secretagogues d'hormone de croissance et d'antidepresseurs, et compositions les contenant
SE0102993D0 (sv) New self emulsifying drug delivery system
MA56607A1 (fr) Méthodes de traitement de troubles dépressifs

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20220923

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4